RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to extend survival in recurrent head and neck cancer
Disease control Recruiting nowThis phase 3 trial tests whether giving radiation and chemotherapy again, followed by the immunotherapy drug pembrolizumab, helps people with recurrent head and neck cancer live longer compared to standard pembrolizumab (with or without chemo). The study includes 214 adults whose…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated May 26, 2026 04:06 UTC
-
Light-Activated drug combo shows promise in head and neck cancer trial
Disease control Recruiting nowThis phase 3 trial tests whether a new light-activated therapy (ASP-1929 photoimmunotherapy) combined with the immunotherapy drug pembrolizumab helps people with recurrent head and neck cancer live longer compared to standard treatments. About 412 adults whose cancer has returned…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Rakuten Medical, Inc. • Aim: Disease control
Last updated May 26, 2026 04:06 UTC
-
Could a Two-Drug punch before surgery beat head and neck cancer?
Disease control Recruiting nowThis study tests whether giving two immunotherapy drugs (cemiplimab and CDX-1140) before surgery works better than one drug alone for people with stage III-IV head and neck cancer. About 44 participants will receive either the combo or just cemiplimab before their tumor is remove…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:01 UTC
-
Cholesterol drug boosts immunotherapy against tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding a common cholesterol-lowering drug (lovastatin) to an immunotherapy (pembrolizumab) can help shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has not responded to prior treatments will rece…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 04:00 UTC
-
New drug combo aims to extend life in Tough-to-Treat head and neck cancer
Disease control Recruiting nowThis phase 3 study tests whether adding ficlatuzumab to standard cetuximab helps people with recurrent or metastatic HPV-negative head and neck cancer live longer or keep their cancer from growing. About 410 adults with confirmed disease and at least one measurable tumor will be …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Could a single immunotherapy drug replace harsh Chemo-Radiation after head and neck cancer surgery?
Disease control Recruiting nowThis study compares the immunotherapy drug pembrolizumab (Keytruda) against the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 with high-risk features (cancer at the …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Promising new combo therapy for recurrent head and neck cancer shows hope
Disease control Recruiting nowThis study is for people whose head and neck cancer has come back after previous radiation. It tests whether giving a type of immunotherapy (pembrolizumab) along with either standard or proton radiation before surgery is safe and works better than surgery alone. About 40 adults w…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated May 26, 2026 03:53 UTC
-
New hope for head and neck cancer: cetuximab after failed immunotherapy
Disease control Recruiting nowThis study is for people with head and neck cancer that has come back or spread. It tests whether the drug cetuximab, given alone, can shrink tumors or slow the disease in patients who no longer benefit from immunotherapy. About 38 adults will take part, and the main goal is to s…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 26, 2026 03:53 UTC
-
New combo therapy aims to outsmart tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding cetuximab to the immunotherapy drug pembrolizumab helps people with advanced head and neck cancer live longer than pembrolizumab alone. The trial enrolls about 158 adults whose cancer has returned or spread and no longer responds to platinum chemot…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with an immunotherapy drug (pembrolizumab), for head and neck cancer that has returned or spread. The study aims to find the safest dose and check for side effects in 40 adul…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Triple therapy aims to reignite immune attack on hard-to-treat head and neck cancer
Disease control Recruiting nowThis study tests whether combining three treatments—modified natural killer cells (PD-L1 t-haNK), an immune-boosting protein (Anktiva), and a targeted antibody (cetuximab)—can shrink tumors in people with advanced head and neck cancer that has come back or spread. About 25 adults…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug combo aims to shrink head and neck tumors in First-Line trial
Disease control Recruiting nowThis study tests whether adding ficerafusp alfa to the standard immunotherapy pembrolizumab helps shrink tumors or extend life in people with PD-L1-positive head and neck cancer that has come back or spread. About 650 adults will receive either the combination or a placebo plus p…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New imaging combo could help surgeons spot hidden head and neck cancer
Diagnosis Recruiting nowThis early-stage trial tests whether combining two imaging techniques can help surgeons better detect and remove head and neck cancer. About 40 adults with squamous cell carcinoma will receive a radioactive tracer before surgery and a fluorescent dye during surgery to highlight c…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated May 26, 2026 04:07 UTC
-
New radioactive tracer could spot hidden cancer spread in head and neck patients
Diagnosis Recruiting nowThis early-stage trial tests a radioactive drug called 111In-panitumumab to see if it can better find cancer that has spread to lymph nodes in people with head and neck cancer. About 30 patients scheduled for surgery will receive the drug and then get a special scan (SPECT/CT) to…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated May 22, 2026 14:03 UTC
-
Morning or afternoon? new study tests best time for cancer immunotherapy
Symptom relief Recruiting nowThis study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 26, 2026 03:56 UTC
-
Cancer patients may soon get infusions at home, cutting travel and stress
Symptom relief Recruiting nowThis study tests whether giving the cancer drug nivolumab as a shot at home is as safe and effective as getting it in a clinic. About 50 adults with various cancers will try both settings to see which they prefer and how it affects their quality of life. The goal is to reduce the…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 26, 2026 03:53 UTC
-
New blood test could forecast head and neck cancer progression
Knowledge-focused Recruiting nowThis observational study enrolls 30 adults with recurrent or metastatic head and neck squamous cell carcinoma. Researchers will collect blood samples to measure circulating tumor cells and immune cell activity, aiming to link these markers with how long patients live without the …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 03:59 UTC
-
Remote hearing tests could save cancer Patients' ears
Knowledge-focused Recruiting nowThis study looks at whether offering hearing tests close to home or online can help more head and neck cancer patients get their hearing checked during treatment. Chemotherapy and radiation can cause hearing loss, but many patients skip follow-up tests. The goal is to see if easi…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 20, 2026 11:54 UTC